medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2013, Número 1

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2013; 11 (1)


Rellenos faciales: efectos adversos

Alcalá D, Martínez GE

Idioma: Español
Referencias bibliográficas: 31
Paginas: 36-41
Archivo PDF: 145.64 Kb.


RESUMEN

Desde fines del siglo XIX se han utilizado materiales para relleno facial con fines terapéuticos y estéticos. Sin embargo, esta práctica se ha convertido en un problema de salud pública debido a las complicaciones precipitadas por malas técnicas de aplicación, uso de materiales cuya seguridad no ha sido demostrada y su administración a manos de personal no médico y mal capacitado.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Thioly-Bensoussan, Daphne. “Non-hyaluronic acid fillers”. Clinics in Dermatology 2008; 26: 160-176.

  2. Lemperle G, Romano JJ, Busso M. “Soft tissue augmentation with Artecoll®: 10-year history, indications, techniques, and complications”. Dermatol Surg 2003; 29: 573-587.

  3. Enríquez MJ, Alcalá Daniel, González Karla, et al. “Lipogranuloma esclerosante por modelantes”. Rev Cent Dermatol Pascua 2007; 16 (1): 19- 23.

  4. Price, Richard D, Berry MG, Navsaria Harshad A. “Hyaluronic acid: the scientific and clinical evidence”. Journal of Plastic, Reconstructive and Aesthetic Surgery 2007; 60: 110-119.

  5. Zimmermann, Ute S, Clerici Thierry J. “The Histological Aspects of Fillers Complications”. Seminars in Cutaneous Medicine and Surgery 2004; 23: 241-250.

  6. Narins RS, Brandt F, Leyden J, et al. “A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correcton of nasolabial folds”. Dermatol Surg 2003; 29: 588-595.

  7. Manna F, Dentini M, Desideri P, de Pita O, Mortilla E, Maras B. “Comparative chemical evaluation of two commercially available derivates of hyaluronic acid (hylaform from rooster combs and restylane from streptococcus) used for soft tissue augmentation”. J Eur Acad Dermatol Venereol 1999; 13: 183-192.

  8. Filion MC, Phillips NC. “Pro-inflammatory activity of contaminating DNA in hyaluronic acid preparations”. J Pharm Pharmacol 2001; 53: 555-561.

  9. Lupton JR, Alster TS. “Cutaneous hypersensitivity reaction to injectable hyaluronic acid gel”. Dermatol Surg 2000; 26: 135-137.

  10. Klein AW. “Granulomatous foreign body reaction against hyaluronic acid”. Dermatol Surg 2004; 30 (7): 1070.

  11. Elson ML. “The role of skin testing in the use of collagen injectable materials”. J Dermatol Surg Oncol 1989; 15: 301-303.

  12. Klein AW, Rish DC. “Injectable collagen update”. J Dermatol Surg Oncol 1984; 10: 519-522.

  13. Morgan AM. “Localized reactions to injected therapeutic materials. Part 2. Surgical agents”. J Cutan Pathol 1995; 22: 289-303.

  14. Vieggaar D. “Soft tissue augmentation and the role of poly-L-lactic acid”. Plast Reconstr Surg 2006; 118 (3 suppl): L46S-54S.

  15. Levy RM, Redbord KP, Hanke CW. “Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study”. J Am Acad Dermatol 2008; 59: 923-933.

  16. Christensen L, Breiting V, Jansen M, Vuust J, Hogdall E. “Adverse reactions to injectable soft tissue permanent fillers”. Aesthetic Plast Surg 2005; 29: 34-48.

  17. Duffy DM. “Complications of fillers. Overview”. Dermatol Surg 2005; 31: 1626-1633.

  18. Zido BM. “Radiance: short term experience”. Aesthet Surg J 2003; 23: 495-499.

  19. Dadzie OE, Mahalingam M, Parada M, El Helou T, Philips T, Bhawan J. “Adverse reactions to soft tissue fillers. A review of the histological features”. J Cutan Pathol 2008; 35: 536-548.

  20. Winer LH, Sternberg TH, Lehman R, Ashley FL. “Tissue reactions to injected silicone liquids”. Arch Dermatol 1964; 90: 588-593.

  21. Rae V, Pardo RJ, Blackwelder PL, Falanga V. “Leg ulcers following subcutaneous injection of a liquid silicone preparation”. Arch Dermatol 1989; 125: 670-673.

  22. Mastruserio DN, Pesqueira MJ, Cobb MW. “Severe granulomatous reaction and facial ulceration after subcutaneous silicone injection”. J Am Acad Dermatol 1996; 34: 849-852.

  23. Hexsel DM, Hexsel CL, Iyengar V. “Liquid injectable silicone. History, mechanism of action, indications, technique, and complications”. Semin Cutan Med Surg 2003; 22: 107-114.

  24. Oliveira VM, Roveda Junior D, Lucas FB, et al. “Late seroma after breast augmentation with silicone prostheses: a case report”. Breast J 2007; 13: 421-423.

  25. Silver RM, Sahn EE, Aleen JA, et al. “Demonstration of silicone in sites of connective tissue disease in patients with silicone gel breast implants”. Arch Dermatol 1993; 129: 63-68.

  26. Varga J, Schumacher R, Jimenez SA. “Systemic sclerosis after augmentation mammoplasty with silicone implants”. Ann Intern Med 1989; 111: 377-387.

  27. Fenske NA, Vasey FB. “Silicone-associated connective tissue disease. The debate rages”. Arch Dermatol 1993; 129: 97-98.

  28. De Cassia Novaes W, Berg A. “Experience with a new non biodegradable hydrogel (Aquamid): a pilot study”. Aesthetic Plast Surg 2003; 27: 376-380.

  29. Duranti F, Salti G, Bovani B, Calandra M, Rosati M. “Injectable hyaluronic acid gel for soft tissue augmentation”. Dermatol Surg 1998; 24: 1317-1325.

  30. Requena Luis, Requena Celia, Christensen Lise, et al. “Adverse reactions of injectable soft tissue fillers”. J Am Acad Dermatol Jan 2011; 64 (1): 1-34.

  31. Valantin MA, Aubron-Olivier C, Ghosn J, et al. “Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA”. AIDS 2003; 17: 2471–2477.




2020     |     www.medigraphic.com